US › Healthcare

Eterna Therapeutics Inc (ERNA)

US · Healthcare · Biotechnology

$3.76-3.84%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.0M

EPS

$-3.40

EPS estimate

$-3.30

EPS came in at -3.40 against a street estimate of -3.30 — a miss of 3.0%.

Key statistics

Market cap

$4.6M

Forward P/E

0.0

P/B

1.49

Book value

$2.73

EPS (TTM)

$-0.39

52-week high

$48.00

52-week low

$3.18

50-day MA

$4.63

200-day MA

$12.17

Beta

2.62

Analyst view

with an average price target of $30.00.

Shareholding

Insiders

29.82%

Institutions

2.18%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.93%
Geode Capital Management, LLC	0.60%
Vanguard Capital Management, LLC	0.06%
Vanguard Fiduciary Trust Co	0.06%
UBS Group AG	0.05%
Tradewinds Capital Management, LLC	0.02%
BlackRock Inc	0.00%
Genworth Financial Wealth Mgmt Inc	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eterna Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.